Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma

Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 4

Abstract

Background and rationale of the study. Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in real-life cohorts. Our aim was to evaluate the impact of liver fibrosis and other variables on HCC incidence in this population of patients. Of 745 patients with chronic hepatitis B (CHB), 306 HBeAg-negative genotype D were selected and included in this study. All patients received treatment with NUC for at least 18 months. Patients with CHB or compensated cirrhosis were included. Patients with HCC diagnosed before or during the first 18 months of NUC therapy were excluded. Results. HCC was diagnosed in 2 CHB patients (1.0%) and 23 cirrhosis patients (20%) (OR = 24.41, 95% CI 5.40 < OR < 153.2; p < 0.0001). Multivariate analysis revealed that HCC risk was independently associated with age ≥ 60 years (OR = 6.45, 95% CI 1.22 to 34.0; p = 0.02) and liver cirrhosis (OR = 12.1, 95% CI 1.39 to 106.2; p = 0.02), but not with virological response (VR), and previous resistance to NUC, or rescue therapy. Multivariate analysis in cirrhosis patients revealed that only age ≥ 60 years was an independent risk factor associated with HCC (p = 0.003). Conclusions. Liver cirrhosis and age ≥ 60 years are the stronger risk factors for HCC in genotype D HBeAgnegative patients. Previous resistance to NUC in patients that achieved a VR after rescue therapy was not a predictive factor regarding HCC. VR does not appear to significantly reduce the overall incidence of HCC when a patient has already progressed to liver cirrhosis.

Authors and Affiliations

Adriano M. Pellicelli, Pascal Vignally, Vincenzo Messina, Antonio Izzi, Ettore Mazzoni, Angelo Barlattani, Donato Bacca, Mario Romano, Fabrizio Mecenate, Tommaso Stroffolini, Caterina Furlan, Umberto V. Gentilucci, Roberto Gulminetti, Maria E. Bonaventura, Cecilia D’Ambrosio, Amerigo Paffetti, Cristina Mastropietro, Massimo Marignani, Lucia Fondacaro, Giuseppe Cerasari, Arnaldo Andreoli, Giorgio Barbarini

Keywords

Related Articles

Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant

Background and rationale. Acoustic radiation force impulse (ARFI) is a non-invasive tool used in the evaluation of liver fibrosisin HCV positive immune-competent patients. This study aimed to assess the accuracy of ARFI...

Determination of ammonia concentrations in cirrhosis patients-still confusing after all these years?

By the end of the nineteenth century, ammonia had been identified as the main factor responsible for hepatic encephalopathy syndrome. Ammonia is one of the principal products of hepatic metabolism and high concentrations...

Prevalence of non-alcoholic fatty liver disease: population based study

Background and aim: Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and liver transplantation in western countries. Increasing incidence of NAFLD has been well documented from Asian c...

Fibrin-mediated integrin signaling plays a critical role in hepatic regeneration after partial hepatectomy in mice

Background. The regenerative capacity of the liver is critical for proper responses to injury. Fibrin extracellular matrix (ECM) deposition is a common response to insult and contributes to inflammatory liver injury. Ho...

Download PDF file
  • EP ID EP78415
  • DOI -
  • Views 116
  • Downloads 0

How To Cite

Adriano M. Pellicelli, Pascal Vignally, Vincenzo Messina, Antonio Izzi, Ettore Mazzoni, Angelo Barlattani, Donato Bacca, Mario Romano, Fabrizio Mecenate, Tommaso Stroffolini, Caterina Furlan, Umberto V. Gentilucci, Roberto Gulminetti, Maria E. Bonaventura, Cecilia D’Ambrosio, Amerigo Paffetti, Cristina Mastropietro, Massimo Marignani, Lucia Fondacaro, Giuseppe Cerasari, Arnaldo Andreoli, Giorgio Barbarini (2014). Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Annals of Hepatology, 13(4), 376-385. https://europub.co.uk/articles/-A-78415